Clinical trials: Muscle Spasticity
Cerebrovascular Accident
A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity
This is a multicenter, double-blind, randomized, placebo-controlled study designed to compare Botulinum Toxin Type A for Injection (HengLi®) with placebo on the efficacy and safety of treatment in post-stroke subjects with focal…
- Trial name
- NCT02280083
- Testing
- Botulinum Toxin Type A for Injection
- Volunteers
- 180 people
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Post-stroke Spasticity of the Lower Limb
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg are effective in treating patients with increased muscle tension/uncontrollable muscle stiffness (spasticity) after a…
- Trial name
- PLUS (NCT01464307)
- Testing
- IncobotulinumtoxinA (400 Units)
- Where
- 53 sites in United States, Canada and 7 more
- Volunteers
- 290 people
- Sponsor
- Merz Pharmaceuticals GmbH
Multiple Sclerosis
Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity
Aim of this randomized, double-blind, placebo-controlled, cross-over study is to investigate cannabinoid-induced changes in neurophysiological parameters in a group of 40 patients with secondary or primary progressive Multiple…
- Trial name
- NS-MSS (NCT01538225)
- Testing
- Sativex®
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Almirall, S.A.
Muscle Spasticity
CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)
The purpose of this study is to evaluate the efficacy and safety of CORETOX® in the treatment of post-stroke upper limb spasticity
- Trial name
- NCT03289702
- Testing
- CORETOX®, BOTOX®
- Where
- South Korea
- Volunteers
- 220 people
- Sponsor
- Medy-Tox
Upper Limb Spasticity After Stroke
A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After Stroke
The purpose of the protocol is to evaluate injection intervals and treatment modalities up to 3 years follow-up of botulinum toxin A (BoNT-A) in adult patients suffering from upper limb spasticity after stroke.
- Trial name
- DECIDE (NCT01239628)
- Where
- 11 sites in Belgium
- Volunteers
- 45 people
- Sponsor
- Ipsen
Upper and/or Lower Limb Focal Spasticity
A Study to Review Treatment Outcomes From Treatment With Dysport® Injections in Adults for Upper and/or Lower Limb Focal Spasticity
The aim of this retrospective study is to describe the real-world outcomes with the treatment of adult patients with Dysport® injections for focal upper limb spasticity (ULS) and/or focal lower limb spasticity (LLS) in NHS…
- Trial name
- DYSCOVER (NCT04604379)
- Where
- 3 sites in United Kingdom
- Volunteers
- 123 people
- Sponsor
- Ipsen
Lower Limb Spasticity
Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity
The purpose of this study is to assess the longitudinal attainment of subject centred and functional related goals (cumulated Goal Attainment Scale Total (GAS T) score) after abobotulinumtoxinA injection (including following…
- Trial name
- NCT03017729
- Testing
- Botulinum toxin type A
- Where
- 27 sites in United States
- Volunteers
- 242 people
- Sponsor
- Ipsen
Upper Limb Spasticity
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
This is a randomized, double-blind, multi-center phase II/III study to evaluate the efficacy and safety of Recombinant Botulinum Toxin Type A (YY001) for injection in the treatment of upper limb spasticity in adults
- Trial name
- NCT06783114
- Testing
- Recombinant Botulinum Toxin Type A for injection (YY001), BOTOX®
- Where
- 24 sites in China
- Volunteers
- 254 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Spasticity
ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity
The objective of this study is to evaluate the effectiveness of BoNT-A on functional improvement in patients with post-stroke upper and/or lower limb spasticity in the early stage of spasticity development, according to routine…
- Trial name
- ETREAT (NCT02275312)
- Where
- 17 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Ipsen
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity Extension Study
The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.
- Trial name
- NCT01313312
- Testing
- Botulinum toxin type A
- Where
- 34 sites in United States, Belgium and 7 more
- Volunteers
- 258 people
- Sponsor
- Ipsen
Sjögren-Larsson Syndrome
A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)
This is a multi-center, randomized, double-blind, vehicle-controlled, parallel-group study designed to evaluate the safety, pharmacokinetic (PK), and exploratory activity of topically-applied NS2 dermatologic cream administered…
- Trial name
- NCT02402309
- Testing
- Active topical NS2 1% dermatologic cream
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Upper Limb Spasticity
Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe.
- Trial name
- NCT05956509
- Testing
- ABBV-950, BOTOX
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- AbbVie
Mumps
Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)
The objective of this post-marketing surveillance study is to collect safety, efficacy and usage data on botulinum injection in subjects with upper or lower limb spasticity on the long-term use in clinical practice and to…
- Trial name
- NCT01390922
- Testing
- Botulinum Toxin Type A
- Volunteers
- 1,038 people
- Sponsor
- GlaxoSmithKline
Spasticity
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of lower limb spasticity, in adults followed by an open-label extension…
- Trial name
- NCT04099667
- Testing
- Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 3; MYOBLOC
- Where
- 9 sites in United States, Hungary and 1 more
- Volunteers
- 40 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Upper Limb Spasticity
Study Evaluating Treatment of Upper Limb Spasticity Using the Cryo-Touch III Device
A proof of concept study to evaluate the feasibility of safe and effective treatment of upper limb spasticity using the Cryo-Touch III Device.
- Trial name
- NCT01863901
- Testing
- Treatment with Cryo-Touch III device
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Post-Stroke Chronic Upper Limb Spasticity
Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.
The purpose of this study is to collect data for Dysport® SMART BoNT-A therapy usage in an office-based setting in post-stroke participants with chronic (> 6 months) focal Upper Limb Spasticity who have been under stable oral…
- Trial name
- SMART-NIS (NCT05224349)
- Where
- 31 sites in Germany
- Volunteers
- 121 people
- Sponsor
- Ipsen
Spasticity With Multiple Sclerosis
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6 [LLMT-6]) in…
- Trial name
- RELEASE MSS5 (NCT04984278)
- Testing
- Nabiximols
- Where
- 30 sites in United States, Czechia and 3 more
- Volunteers
- 56 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Spasticity, Muscle
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disease of the central nervous system (CNS) that is regarded as the foremost cause of non-traumatic neurologic disability in adults in North America.
- Trial name
- OS440-3004 (NCT03290131)
- Testing
- Arbaclofen
- Where
- 30 sites in Belarus, Bosnia and Herzegovina and 5 more
- Volunteers
- 536 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Upper Limb Injury
CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity
The aim of this study is to perform, in real world clinical practice, a three-dimensional assessment from patient's, caregiver's and physician's perspectives, of the impact of AboBoNT-A on caregiver burden, functional disability…
- Trial name
- CARBUR (NCT06245772)
- Where
- 27 sites in France
- Volunteers
- 113 people
- Sponsor
- Ipsen
Spinal Cord Injury, Muscle Spasticity
Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury
Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs.
- Trial name
- NCT00041717
- Testing
- Fampridine-SR
- Where
- 45 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Acorda Therapeutics